← Back to the boardNews
Armata Pharmaceuticals Announces Financial Results for the Third Quarter 2026 and Provides Corporate Update
Why it’s here: Armata's Q3 earnings release is mainly a company update, but it discloses FDA Breakthrough Therapy designation, an FDA End-of-Phase 2 process, and $3.7M in additional Department of War funding for a biotech product, which bears on federal biotech regulation and defense-funded biodefense.
Item
2d agoPR NewswireArmata Pharmaceuticals Announces Financial Results for the Third Quarter 2026 and Provides Corporate UpdateArmata Pharmaceuticals received $3.7 million in additional DoW non-dilutive funding through MTEC for AP-SA02 Phase 3 execution, bringing cumulative award funding to about $32.4 million.1 outletBiotech
About
- Department of Defense
- Food and Drug Administration